

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Healthia Limited
ABN	85 626 087 223

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Anthony Peter Ganter
Date of last notice	20 December 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	<ol style="list-style-type: none"> 1. Indirect 2. Indirect 3. Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ol style="list-style-type: none"> 1. Anthony Peter Ganter & Deborah Lee Huber as trustee for the Ganter Huber Super Fund. Anthony Peter Ganter is trustee and beneficiary of the super fund. 2. Ganter Huber Holdings Pty Ltd as trustee for the Ganter Huber Family Trust. Anthony Peter Ganter is the sole director and a shareholder of the trustee and an appointor of the trust. 3. Anthony Peter Ganter
Date of change	<ol style="list-style-type: none"> 1. Not applicable 2. Not applicable 3. 19 November 2021
No. of securities held prior to change	<ol style="list-style-type: none"> 1. 625,819 2. 312,403 3. 218,115
Class	<ol style="list-style-type: none"> 1. Ordinary Class Shares 2. Ordinary Class Shares 3. Performance Rights – each being a conditional entitlement to one ordinary share in the Company in accordance with the Company's Performance Rights Plan.
Number acquired	<ol style="list-style-type: none"> 1. Nil 2. Nil 3. 36,000

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	<ol style="list-style-type: none"> 1. Nil 2. Nil 3. Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ol style="list-style-type: none"> 1. Not applicable 2. Not applicable 3. Performance Rights form part of Directors' remuneration and are issued for nil consideration
No. of securities held after change	<ol style="list-style-type: none"> 1. 625,819 2. 312,403 3. 254,115
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<ol style="list-style-type: none"> 1. Not applicable 2. Not applicable 3. Security holder approval was obtained at Healthia's Annual General Meeting held on 17 November 2021, to issue performance rights to Directors pursuant to the Company's Performance Rights Plan (the Plan), (of which the Plan was approved by shareholders at Healthia's Annual General Meeting on 20 November 2019).

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.